Săftescu Sorin, Negru Șerban, Volovăț Simona, Popovici Dorel, Chercota Vlad, Stanca Simona, Feier Horea, Malita Daniel, Dragomir Radu, Volovăț Constantin
Department of Oncology, 'Victor Babeş' University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Department of Oncology, 'Gr. T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.
Exp Ther Med. 2021 Jun;21(6):605. doi: 10.3892/etm.2021.10037. Epub 2021 Apr 14.
Checkpoint inhibitors represent the first therapeutic class to replace chemotherapy lines for the treatment of metastatic non-small cell lung cancer (NSCLC), due to improved overall survival and tolerability. Nivolumab, a fully human anti-programmed cell death-1 immunoglobulin G4 monoclonal antibody, is the first immune checkpoint inhibitor approved by the US Food and Drug Administration in 2014 for cases of metastatic melanoma and in 2015 for cases of squamous cell lung cancer and kidney cell cancer. The present study aimed to identify predictive markers (favorable or unfavorable) for time to treatment discontinuation using nivolumab in the second or subsequent line of therapy of metastatic NSCLC cases. Analysis of a group of 78 NSCLC patients treated with nivolumab allowed the identification of negative predictive markers, related to the presence of metastases (adrenal in men under 65 years, liver, brain and the number of metastatic sites) and the hematological profile (neutrophilia at the initiation of treatment and lymphocyte variation at 6 weeks of treatment).
由于总体生存率和耐受性得到改善，检查点抑制剂成为首个取代化疗方案用于治疗转移性非小细胞肺癌（NSCLC）的治疗类别。纳武单抗是一种全人源抗程序性细胞死亡蛋白1免疫球蛋白G4单克隆抗体，是2014年美国食品药品监督管理局批准用于治疗转移性黑色素瘤、2015年批准用于治疗肺鳞状细胞癌和肾细胞癌的首个免疫检查点抑制剂。本研究旨在确定在转移性NSCLC病例的二线或后续治疗中使用纳武单抗时治疗中断时间的预测标志物（有利或不利）。对一组78例接受纳武单抗治疗的NSCLC患者进行分析，确定了与转移灶存在（65岁以下男性的肾上腺转移、肝转移、脑转移以及转移部位数量）和血液学特征（治疗开始时的中性粒细胞增多和治疗6周时的淋巴细胞变化）相关的阴性预测标志物。
